Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 286 to 300 of 1243 results for public health guidance

  1. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    Awaiting development Reference number: GID-TA11425 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]

    Awaiting development Reference number: GID-TA11049 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]

    Awaiting development Reference number: GID-TA11335 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies [TSID12150]

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]

    Awaiting development Reference number: GID-TA10957 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]

    Awaiting development Reference number: GID-TA11111 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development